Le Lézard
Classified in: Health, Science and technology

Asymmetrik Launches Phoenix Enterprise FHIR® Server Amidst 21st Century Cures Deadline


ANNAPOLIS, Md., Aug. 11, 2020 /PRNewswire-PRWeb/ -- Asymmetrik, a leader in software development and data analytics, launches Phoenix Enterprise FHIR® Server; empowering developers, providers, and payers to build new integrations, clinical workflows and applications. Phoenix Enterprise FHIR® Server will help payers comply with the latest ONC 21st Century Cures regulations which mandates insurers offering Medicare or Medicaid plans to implement and maintain a secure, FHIR® Patient Access Application Programming Interface (API); to enable patients to easily access billing data, encounter information, and clinical data.

Asymmetrik's official open source secure FHIR Server has been a long time favorite among software developers in digital healthcare. Using the Phoenix Enterprise FHIR® Server, healthcare organizations can:

API standard (HL7 FHIR®)

provenance controls

acquisition and engagement, and research

The newly released Phoenix Enterprise is multi-versioning, enabling industry partners to convert their data to any HL7 FHIR format, regardless of their existing connected system or data format."Written in Node.JS, and with modern design patterns, the Phoenix FHIR® Server is capable of supporting DSTU2, STU3, and R4 (Release 4) FHIR versions, making it an ideal contribution to the data interoperability space", states Shane O'Neill, Asymmetrik Developer, "With the ability to scale horizontally on-demand and leverage any PostgreSQL instance (e.g. AWS RDS), our Enterprise variant is extremely performant. Continued R4 support allows compatibility with CMS Blue Button 2.0"

"We're extremely excited to launch a server that complies with the most recent federal mandates, as well as the overall industry goal of bringing healthcare data into the hands of the consumer and advancing new development and innovations" says Amit Singh, Asymmetrik's Chief Technology Officer.

For more information about Asymmetrik FHIR Server contact:
fhir@asymmetrik.com, or visit: https://asymmetrik.com/solutions/healthcare/

About Asymmetrik Ltd.: Asymmetrik Ltd. (http://www.asymmetrik.com) is a Maryland-based company whose digital healthcare solutions create a positive impact for both patients and health systems. Our user-centered design approach promotes greater accessibility and can dramatically improve patient and physician satisfaction. Using our extensive expertise in systems interoperability, data analytics and UX optimization, we help hospitals and health systems improve the cost and quality of care.

 

SOURCE ASYMMETRIK LTD


These press releases may also interest you

at 12:35
AstraZeneca and Merck , known as MSD outside the United States and Canada, today announced final results from the Phase III PROfound trial that showed LYNPARZA (olaparib) demonstrated a statistically significant and clinically meaningful improvement...

at 12:35
AstraZeneca and Merck , known as MSD outside the United States and Canada, today announced final results from the Phase 3 PROfound trial which showed LYNPARZA demonstrated a statistically significant and clinically meaningful improvement in overall...

at 12:00
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "There have been 142,774 cases of COVID-19 in Canada, including 9,211 deaths. 87% of people have now recovered....

at 11:00
The most recent data on the evolution of COVID-19 in Québec show 462 new cases, bringing the total number of people infected to 67,542. Also, 1 new death has occurred in the last 24 hours, to which are added 4 deaths which have occurred between...

at 11:00
The Auden Living group of modern housing complexes developed by DMG Investments has announced a new discount program for frontline workers. Through the housing company's Our Heroes Program and their Military and Veterans Program, their housing...

at 10:25
Merck , known as MSD outside the United States and Canada, today announced the presentation of new data for three investigational medicines in Merck's diverse and expansive oncology pipeline: vibostolimab (MK-7684), an anti-TIGIT therapy; MK-4830, a...



News published on 11 august 2020 at 14:00 and distributed by: